MPE8 antibody hits the Achilles heel of the viruses Davide Corti

Transcription

1 Press Release Publication in the scientific journal Nature: a human antibody that neutralizes 4 different viruses and has the potential to prevent and treat severe lower respiratory tract infections Discovery by the Swiss Biotech company Humabs BioMed in collaboration with the Institute for Research in Biomedicine Scientific progress confirms successful partnership between Humabs BioMed and the Institute for Research in Biomedicine BELLINZONA (Switzerland) August 20, 2013 A publication in the renowned scientific journal Nature describes a unique human monoclonal antibody (MPE8) discovered by the Swiss Biotech company Humabs BioMed SA in collaboration with the Institute for Research in Biomedicine (IRB) which is affiliated to the Università della Svizzera Italiana (USI). Humabs, a privately owned spin-off company of the IRB, is focusing on the discovery of next-generation human monoclonal antibodies to treat infectious and inflammatory diseases. The study, which involved collaborators from the Policlinico San Matteo IRCCS, Pavia (IT) and the University of Lausanne (CH), was partially funded by the Swiss National Science Foundation and the European Research Council. MPE8, a unique antibody that neutralizes different viruses MPE8 is the first neutralizing antibody that targets four different human and animal viruses, in particular the respiratory syncytial virus (RSV) and the metapneumovirus (MPV) that cause severe lower respiratory tract infections. MPE8 represents a new promising drug for the prophylaxis as well as for the therapy of respiratory infections in infants and immunosuppressed patients. MPE8 also identifies a conserved structure shared by different viruses, which could lead to the development of a new vaccine capable of conferring protection against multiple viruses. High medical need to treat patients infected by RSV and MPV viruses RSV and MPV are a prominent cause of respiratory diseases ranging from common cold to severe infection of the lower respiratory tract and have been

2 implicated in the development of asthma. RSV and MPV infections can be fatal in newborns and in immunosuppressed patients who have undergone stem cell or lung transplantation with a mortality up to 40%. A humanized antibody to RSV (Synagis) is currently used for prophylaxis in premature newborns, but is not effective therapeutically. There are no antibodies to prevent MPV infection. Furthermore, vaccines against RSV and MPV are not available. Given the high prevalence of these pathogens and the severity of the diseases caused, there is a strong medical need to develop novel therapies against these deadly viruses. The figure illustrates a section of multinucleated "syncytia" that are formed by the fusion of multiple adjacent cells induced by RSV infection (membranes and nuclei are shown in red and blue, respectively). MPE8 antibody hits the Achilles heel of the viruses Davide Corti, Head of antibody discovery at Humabs BioMed and first author of the study comments: This is a remarkable example of the power of the Humabs discovery platform to select, from the human immune response, antibodies with unique properties. Out of the several antibodies identified that neutralized either RSV or MPV, MPE8 was the only one that potently neutralized both viruses. Surprisingly, MPE8 is also active against two other paramyxoviruses of animal origin: bovine RSV and pneumonia virus of mice. Importantly we have been able to test MPE8 in a relevant animal model and found that the antibody has not only prophylactic but also therapeutic activity in a situation where ribavirin, the only antiviral drug available to treat with limited efficacy severe infections in humans, is ineffective. MPE8 antibody binds to the viral fusion protein in a site that is conserved among different viruses and represents a kind of Achilles heel of these viruses. We hope to be able to use this information to develop a new vaccine capable of protecting against multiple viruses. 2

3 Phylogenetic tree highlighting the high level of genetic distance of the 4 different paramyxoviruses neutralized by the MPE8 antibody Antonio Lanzavecchia, director of the Institute for Research in Biomedicine; Professor of Human Immunology at the ETH Zurich, scientific founder of Humabs and senior author of the study comments: After the isolation of an antibody that neutralizes all human and animal influenza viruses that we reported two years ago in the journal Science the identification of MPE8, which neutralizes 4 different paramixoviruses, is a further demonstration of the potential of the antibody discovery technologies that we developed 10 years ago. At that time nobody would have expected that antibodies with such potency and breadth of neutralization could exist. MPE8 is the first antibody that can neutralize viruses belonging to different species. Given its potency and breadth, we are confident that MPE8 represents a strong candidate for prophylaxis and therapy of these life threatening infections. Model of the pre-fusion F proteins on the RSV membrane with highlighted in red the "Achilles' heel" of the virus targeted by the MPE8 Exemplary cooperation between university and industry The discovery of MPE8 is the result of a close collaboration between the IRB, a non-profit Institute performing basic research, and its spin-off, Humabs BioMed, which has licensed the antibody discovery technology developed at IRB and has the resources to bring the antibody to the clinic. This also includes discussions with potential pharmaceutical partners interested in the clinical development of the antibody. IRB and Humabs are complementing each other in promoting the 3

4 medical progress in the treatment of infectious and other debilitating diseases. Alcide Barberis, President and CEO of Humabs comments: This work is an example of the successful and long lasting partnership between the Institute for Research in Biomedicine (IRB) and Humabs and confirms the potential of our Humabs discovery platform to select highly effective human monoclonal antibodies. The exciting results published in Nature showing the unique properties of the discovered antibody have raised high interest among clinicians in the field. Synagis (a humanized antibody) is the only RSV-treatment on the market with annual sales close to 1 billion USD. The pool of patients who may need novel RSV and MPV therapies is considerably larger than the group that is currently treated with Synagis. Over the next decade the market could expand to reach atrisk adults, elderly and children suffering from acute infections. Humabs is in discussions with pharmaceutical companies that have shown interest in bringing the antibody into clinical stages of development. About Humabs Humabs is a privately owned Swiss Biotech company incorporated as a spin-off of the Institute for Research in Biomedicine (IRB). The company discovers and develops next-generation fully human monoclonal antibodies. The discovery technologies have been developed at the IRB by Professor Dr. Antonio Lanzavecchia and have been out licensed to Humabs in Humabs is focusing on the creation of unique antibodies to treat infectious and inflammatory diseases for clinical development through pharmaceutical partners. The company has already partnered with two major pharmaceutical companies for taking two of its programs, anti HCMV and anti FluA & FluB antibodies, to clinical development. About the Institute for Research in Biomedicine (IRB) and the Università della Svizzera Italiana (USI) The Institute for Research in Biomedicine (IRB), founded in 2000 in Bellinzona, has been affiliated to the Università della Svizzera Italiana (USI) in Financed by private and public institutions, and by competitive grants, the IRB currently hosts nine research groups and 80 researchers. Research focuses on the human host defense against infections, tumors and degenerative diseases. With more than 330 publications in leading scientific journals, the IRB has gained an international reputation as a center of excellence in immunology and cell biology. ww.irb.usi.ch 4

5 Article reference Corti et al 'Cross-neutralization of four paramyxoviruses by a human monoclonal antibody'. DOI: /nature Advance Online Publication (AOP) on Further information and illustrations are available from: Antonio Lanzavecchia: Lanzavecchia@irb.usi.ch tel: Davide Corti: davide.corti@humabs.ch tel: Alcide Barberis: alcide.barberis@humabs.ch tel: Media Contact: IRF Communications AG Daniel Piller, Partner Raemistrasse 4 P.O. Box, CH-8024 Zürich T F daniel.piller@irfcom.ch Forward-looking statements. This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Humabs BioMed. Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; trends toward health care cost containment; and increased scrutiny of the healthcare industry by government agencies. 5